UK markets closed
  • FTSE 100

    7,503.42
    +113.44 (+1.54%)
     
  • FTSE 250

    20,119.98
    +284.03 (+1.43%)
     
  • AIM

    963.43
    +6.79 (+0.71%)
     
  • GBP/EUR

    1.1769
    -0.0053 (-0.45%)
     
  • GBP/USD

    1.2570
    +0.0075 (+0.60%)
     
  • BTC-GBP

    24,203.52
    +407.64 (+1.71%)
     
  • CMC Crypto 200

    682.48
    +7.60 (+1.13%)
     
  • S&P 500

    3,973.44
    +72.08 (+1.85%)
     
  • DOW

    31,952.77
    +690.87 (+2.21%)
     
  • CRUDE OIL

    110.71
    +0.43 (+0.39%)
     
  • GOLD FUTURES

    1,851.30
    +9.20 (+0.50%)
     
  • NIKKEI 225

    27,001.52
    +262.49 (+0.98%)
     
  • HANG SENG

    20,470.06
    -247.18 (-1.19%)
     
  • DAX

    14,140.40
    +158.49 (+1.13%)
     
  • CAC 40

    6,336.02
    +50.78 (+0.81%)
     

Global Pharma and Biotech Royalty Rate Trends Report 2022: Technology Licensed, Royalty Rates, License Fees, Upfront and Milestone Payments

·6-min read
Company Logo
Company Logo

Dublin, May 09, 2022 (GLOBE NEWSWIRE) -- The "Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2022" report has been added to ResearchAndMarkets.com's offering.

The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2022 report is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.

This report provides details of the latest partnering deals which disclose a royalty rate, announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of partnering deals disclosing royalty rates from 2010 to 2022.

The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all partnering deals announced since 2010 where a quantitative royalty rate has been disclosed, as recorded in the Current Agreements deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of royalty rate trends in pharma and biotech since 2010. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in royalty rates in the pharma and biotech sectors since 2010, including a summary of the recent literature on the subject.

Chapter 3 provides a more detailed insight into the structure of a royalty rate clause and how it fits with the other financial terms of the partnering deal. The chapter includes numerous case studies for actual deals where royalty rates have been disclosed.

Chapter 4 provides an insight into companies active in disclosing royalty rates as well as those deals attracting the highest royalty rates, and why.

Chapter 5 provides comprehensive and detailed access to deals which disclose a royalty rate since 2010 where a contract document is available. Contract documents provide an in-depth insight into the actual deal terms agreed between the parties with respect to the royalty rate.

In addition the report includes a comprehensive appendix listing of all deals where a royalty rate has been disclosed announced since 2010. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area, and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

In conclusion, this report provides everything a prospective dealmaker needs to know about royalty rates in the pharma and biotech sector.

Key benefits

  • In-depth understanding of royalty rate partnering deal trends since 2010

  • Analysis of the structure of royalty clauses with numerous real life case studies

  • Comprehensive listing of all partnering deals since 2010 where a royalty rate is disclosed, together with deal terms, value and press release

  • Comprehensive access to actual partnering deal contracts entered into by the world's life science companies where a royalty rate is disclosed

  • Insight into the royalty terms included in a licensing agreement, together with real world clause examples

  • Understand the key deal terms companies have agreed in previous deals

  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Available deals and contracts are listed by:

  • Company A-Z

  • Headline value

  • Therapeutic area

  • Technology type

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise royalty rates granted?

  • What is actually granted by the agreement to the partner company?

  • What exclusivity is granted?

  • What is the payment structure for the deal?

  • How are sales and payments audited?

  • What is the deal term?

  • How are the key terms of the agreement defined?

  • How are IPRs handled and owned?

  • Who is responsible for commercialization?

  • Who is responsible for development, supply, and manufacture?

  • How is confidentiality and publication managed?

  • How are disputes to be resolved?

  • Under what conditions can the deal be terminated?

  • What happens when there is a change of ownership?

  • What sublicensing and subcontracting provisions have been agreed?

  • Which boilerplate clauses does the company insist upon?

  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

  • Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction
1.1. What are royalties?
1.2. History of royalty rates
1.3. Royalties in pharma and biotech
1.4. Royalties versus revenue share
1.5. Overview of the report

Chapter 2 - An overview of pharma and biotech royalty rates
2.1. Trends in royalty rates 2010-2022
2.2. How do revenue shares figure?
2.3. A review of recent literature
2.4. Royalty rates in the future

Chapter 3 - The royalty clause in pharma and biotech deals
3.1. Partnering agreement structure
3.2. Structure of a typical royalty clause
3.3. Example royalty clauses
3.3.1. Case study 1
3.3.2. Case study 2
3.3.3. Case study 3
3.3.4. Case study 4

Chapter 4 - Companies actively disclosing royalty rates
4.1. 25 most active companies in disclosing royalty rates
4.2. Top partnering deals by royalty rate
4.3. Top partnering deals by royalty rate

Chapter 5 - Royalty rate contract directory
Explore royalty rates within the deal contract document to gain greater insight

Appendices
Appendix 1 - Royalty rates in deals - by company A-Z
Appendix 2 - Royalty rates in deals - by therapy area
Appendix 3 - Royalty rates in deals - by stage of development at signing
Appendix 4 - Royalty rates in deals - by technology type
Appendix 5 - Royalty rate references
Appendix 6 - Example royalty rate deal contract document

For more information about this report visit https://www.researchandmarkets.com/r/ef1483

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting